COSMOS HEALTH INC (COSM)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$0.27+2.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
Intact: The reason to own it still holds.
Cosmos Health grew revenue 31% in Q1 to $17.9M. They aim for $155.8M revenue by 2027. A new manufacturing deal and U.S. expansion support growth. The recent buyback shows confidence in the company.
The company is loss-making and missed earnings several times. Revenue fell from $19.7M in Q4 2025 to $17.9M in Q1 2026. The stock is down 37% from its high. Legal and listing issues add risk.
The market prices in a weak turnaround with losses and earnings misses. There is no clear consensus revenue growth or fair value. Our view is cautious given recent misses and stock weakness.
Breaks if: No buybacks announced or buybacks halted
Breaks if: EPS stays below $0.03 per share in FY 2027
Breaks if: revenue falls below $110 million in FY 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
COSM represents a speculative growth investment. It is currently in a watch state, with recent financial performance showing some recovery, but still facing significant risks and challenges ahead.
The market seems to be pricing in a cautious outlook, given the company's loss-making status and high risk. Expectations may be tempered due to the elevated probability of an earnings miss in the near term.
Management is focused on expanding its U.S. market presence, which has shown positive revenue growth. However, the company continues to struggle with negative operating cash flow, indicating that achieving profitability remains a challenge.
The long-term thesis hinges on management's ability to execute on growth initiatives and the overall health of the healthcare sector. Key factors include potential earnings guidance cuts and the performance of sector bellwethers, which could influence sentiment.
In the next 1 to 3 years, COSM's trajectory will depend on its operational execution and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company expects over $6 million in new revenue from the Oliv18 product. This could improve overall revenue and margins. However, the company recently missed earnings estimates. This raises concerns about reaching its revenue target of $155.8 million by 2027.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.